Asset profile
Tislelizumab
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: Esophageal Squamous Cell Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Featured evidence outside covered markets:NCT03412773 · Hepatocellular Carcinoma (HCC) · Phase 3 · completed · ungraded
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
23 competitors in this universe: 0 direct rivals (same mechanism and indication), 23 same-class, 0 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tislelizumab: this drug | Approved | Monoclonal antibody | PD-1 | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Nivolumab | Approved | Monoclonal antibody | PD-1 | ||
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab Berahyaluronidase Alfa | Approved | Monoclonal antibody | PD-1 | ||
| Retifanlimab | Approved | Monoclonal antibody | PD-1 | ||
| Toripalimab | Approved | Monoclonal antibody | PD-1 | ||
| Abp 234 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Balstilimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| CT-P51 | Phase 3 | Small molecule | PD-1 | ||
| Dostarlimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | ||
| MB12 | Phase 3 | Monoclonal antibody | PD-1 |
…and 8 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(228 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (46)
October 2026 (3)
Phase 2Advanced Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2026-10-31 · NCT05652192 · CT.gov ↗
What to watch
Phase 2Tongue Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2026-10-31 · NCT07346807 · CT.gov ↗
What to watch
Early phase / not applicableAdvanced Solid TumorNot yet recruiting
Est. primary completion 2026-10-31 · NCT07396090 · CT.gov ↗
What to watch
November 2026 (6)
Phase 2MSI-H/dMMR Solid TumorsRecruiting
Est. primary completion 2026-11 · NCT03736889 · CT.gov ↗
What to watch
Phase 3Advanced and Metastatic NSCLCNot yet recruiting
Est. primary completion 2026-11 · NCT06704620 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal MetastasisActive not recruiting
Est. primary completion 2026-11-01 · NCT06914687 · CT.gov ↗
What to watch
Phase 2B-NHL, CART TherapyRecruiting
Est. primary completion 2026-11-20 · NCT06695013 · CT.gov ↗
What to watch
Phase 2Lung CancerRecruiting
Est. primary completion 2026-11-30 · NCT06749886 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-11-30 · NCT06725498 · CT.gov ↗
What to watch
December 2026 (37)
Phase 1Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal CancerActive not recruiting
Est. primary completion 2026-12 · NCT05789069 · CT.gov ↗
What to watch
Phase 1Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma …Active not recruiting
Est. primary completion 2026-12 · NCT05238883 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast Cancer, Bone MetastasesRecruiting
Est. primary completion 2026-12 · NCT06538896 · CT.gov ↗
What to watch
Phase 2Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal MetastasisActive not recruiting
Est. primary completion 2026-12 · NCT07512674 · CT.gov ↗
What to watch
Phase 2NK/T Cell LymphomaRecruiting
Est. primary completion 2026-12 · NCT07000617 · CT.gov ↗
What to watch
Phase 2Thymic Carcinoma, ThymomaRecruiting
Est. primary completion 2026-12 · NCT06838910 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2026-12 · NCT05531123 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06177301 · CT.gov ↗
What to watch
Early phase / not applicableHCC - Hepatocellular Carcinoma, TP53 Gene Mutation, Unresectable, Resistant CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07535840 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant Solid TumorsRecruiting
Est. primary completion 2026-12-01 · NCT06499350 · CT.gov ↗
What to watch
Phase 2Rectal Cancer PatientsRecruiting
Est. primary completion 2026-12-01 · NCT06647680 · CT.gov ↗
What to watch
Phase 2Recurrent Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT04615143 · CT.gov ↗
What to watch
Phase 2/3Locally Advanced Rectal CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT06312982 · CT.gov ↗
What to watch
Phase 1HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted TherapyRecruiting
Est. primary completion 2026-12-15 · NCT06741982 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)Recruiting
Est. primary completion 2026-12-24 · NCT05768932 · CT.gov ↗
What to watch
Phase 2DLBCLActive not recruiting
Est. primary completion 2026-12-28 · NCT05253118 · CT.gov ↗
What to watch
Phase 2Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxelRecruiting
Est. primary completion 2026-12-30 · NCT07126119 · CT.gov ↗
What to watch
Phase 2Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor, Kidney-sparing, Nab-paclitaxelRecruiting
Est. primary completion 2026-12-30 · NCT07233252 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT06664021 · CT.gov ↗
What to watch
Phase 2Neoadjuvant ImmunotherapyRecruiting
Est. primary completion 2026-12-30 · NCT05837806 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC, Head Cancer NeckNot yet recruiting
Est. primary completion 2026-12-30 · NCT06366945 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT06356597 · CT.gov ↗
What to watch
Phase 3Gastroesophageal Junction Adenocarcinoma, Gastric AdenocarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT06206733 · CT.gov ↗
What to watch
Phase 1SCLC, Extensive StageRecruiting
Est. primary completion 2026-12-31 · NCT07413042 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Cancinoma (NPC), SBRT, ImmunotherapyRecruiting
Est. primary completion 2026-12-31 · NCT06676722 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT06238167 · CT.gov ↗
What to watch
Phase 2Biliary Tract CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05668884 · CT.gov ↗
What to watch
Phase 2Gastric Cancer Peritoneal MetastasesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07304258 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06536868 · CT.gov ↗
What to watch
Phase 2Esophagus CancerRecruiting
Est. primary completion 2026-12-31 · NCT06430658 · CT.gov ↗
What to watch
Phase 3Gastric Cancer Stage IIIActive not recruiting
Est. primary completion 2026-12-31 · NCT06939439 · CT.gov ↗
What to watch
Phase 3Advanced CholangiocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05823311 · CT.gov ↗
What to watch
Phase 3B-cell MalignanciesActive not recruiting
Est. primary completion 2026-12-31 · NCT04170283 · CT.gov ↗
What to watch
Early phase / not applicableEsophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07067450 · CT.gov ↗
What to watch
2027 (91)
January 2027 (7)
Phase 1/2Colorectal CarcinomaNot yet recruiting
Est. primary completion 2027-01-01 · NCT07025850 · CT.gov ↗
What to watch
Phase 2SCLC, Extensive StageNot yet recruiting
Est. primary completion 2027-01-15 · NCT06793228 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-15 · NCT07320105 · CT.gov ↗
What to watch
Phase 1/2KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer …Active not recruiting
Est. primary completion 2027-01-25 · NCT04699188 · CT.gov ↗
What to watch
Phase 3Lung Cancer (NSCLC)Recruiting
Est. primary completion 2027-01-30 · NCT06598527 · CT.gov ↗
What to watch
Phase 2Small Cell Lung Cancer Extensive StageNot yet recruiting
Est. primary completion 2027-01-31 · NCT06851819 · CT.gov ↗
What to watch
Phase 2Refractory Solid Cancer Patients Unexposed to ImmunotherapyNot yet recruiting
Est. primary completion 2027-01-31 · NCT07300891 · CT.gov ↗
What to watch
February 2027 (2)
March 2027 (9)
Phase 1Advanced Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2027-03 · NCT07348107 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2027-03-01 · NCT06838208 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocellular CarcinomaRecruiting
Est. primary completion 2027-03-15 · NCT06860477 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
Phase 1/2Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer …Recruiting
Est. primary completion 2027-03-31 · NCT06427941 · CT.gov ↗
What to watch
Phase 2ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin, EGFR ADC, PD-1 InhibitorNot yet recruiting
Est. primary completion 2027-03-31 · NCT07531979 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-03-31 · NCT07413354 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2027-03-31 · NCT07104604 · CT.gov ↗
What to watch
April 2027 (2)
May 2027 (7)
Phase 1NSCLC (Advanced Non-small Cell Lung Cancer)Recruiting
Est. primary completion 2027-05 · NCT06969612 · CT.gov ↗
What to watch
Phase 2Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9, Tislelizumab, RandomizedRecruiting
Est. primary completion 2027-05-05 · NCT07458529 · CT.gov ↗
What to watch
Phase 1HPV-positive Oropharyngeal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-10 · NCT07565740 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-05-15 · NCT06383780 · CT.gov ↗
What to watch
Phase 1/2Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT05886439 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-30 · NCT06354140 · CT.gov ↗
What to watch
Phase 1/2HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted TherapyActive not recruiting
Est. primary completion 2027-05-31 · NCT07010120 · CT.gov ↗
What to watch
June 2027 (12)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-06 · NCT05978102 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC), Portal Vein Tumor ThrombusRecruiting
Est. primary completion 2027-06 · NCT07483359 · CT.gov ↗
What to watch
Phase 2Carcinoma, Hepatocellular, Liver Cell CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT05366829 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer …Active not recruiting
Est. primary completion 2027-06-30 · NCT05651022 · CT.gov ↗
What to watch
Phase 2Lung Cancer, Non-small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT06877299 · CT.gov ↗
What to watch
Phase 2Resectable NSCLCRecruiting
Est. primary completion 2027-06-30 · NCT07050056 · CT.gov ↗
What to watch
Phase 2NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant ImmunotherapyNot yet recruiting
Est. primary completion 2027-06-30 · NCT06977828 · CT.gov ↗
What to watch
Phase 2HCC, Liver Cirrhosis, Portal HypertensionNot yet recruiting
Est. primary completion 2027-06-30 · NCT07350070 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Follicular LymphomaNot yet recruiting
Est. primary completion 2027-06-30 · NCT07031700 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT07845916 · CT.gov ↗
What to watch
Phase 3Gastric Cancer StageNot yet recruiting
Est. primary completion 2027-06-30 · NCT07068516 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-06-30 · NCT03967977 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct CancerRecruiting
Est. primary completion 2027-07-01 · NCT07030140 · CT.gov ↗
What to watch
Phase 2Prostate Cancer, Stage IV Prostate CancerActive not recruiting
Est. primary completion 2027-07-15 · NCT05189457 · CT.gov ↗
What to watch
August 2027 (6)
Phase 1Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma …Recruiting
Est. primary completion 2027-08 · NCT07059299 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-08 · NCT04501523 · CT.gov ↗
What to watch
Phase 2Richter TransformationRecruiting
Est. primary completion 2027-08 · NCT04271956 · CT.gov ↗
What to watch
Phase 2Esophagus CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT07046221 · CT.gov ↗
What to watch
Phase 2NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxelRecruiting
Est. primary completion 2027-08-10 · NCT07089199 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2027-08-10 · NCT07469306 · CT.gov ↗
What to watch
September 2027 (7)
Phase 2Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-09-01 · NCT06560528 · CT.gov ↗
What to watch
Phase 2Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT05359393 · CT.gov ↗
What to watch
Phase 2Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response RateNot yet recruiting
Est. primary completion 2027-09-20 · NCT07145931 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2027-09-28 · NCT06233942 · CT.gov ↗
What to watch
Phase 1Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT07317609 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung Cancer (Stage III)Not yet recruiting
Est. primary completion 2027-09-30 · NCT06908733 · CT.gov ↗
What to watch
Phase 3Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint InhibitorsNot yet recruiting
Est. primary completion 2027-09-30 · NCT07132008 · CT.gov ↗
What to watch
October 2027 (2)
November 2027 (4)
Phase 3Colorectal Cancer, Microsatellite Instability HighRecruiting
Est. primary completion 2027-11-01 · NCT06520683 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-11-01 · NCT07243691 · CT.gov ↗
What to watch
Phase 1Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRTNot yet recruiting
Est. primary completion 2027-11-30 · NCT07453875 · CT.gov ↗
What to watch
Phase 2Neoadjuvant Immunotherapy, NSCLC, Chemo-free TherapyNot yet recruiting
Est. primary completion 2027-11-30 · NCT07231575 · CT.gov ↗
What to watch
December 2027 (30)
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2027-12 · NCT05547321 · CT.gov ↗
What to watch
Phase 1/2Non Small Cell Lung Cancer, Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2027-12 · NCT05431270 · CT.gov ↗
What to watch
Phase 1/2Rectal CancerRecruiting
Est. primary completion 2027-12 · NCT07561060 · CT.gov ↗
What to watch
Phase 1/2RAS Mutation, Non-small Cell Lung Cancer (NSCLC)Not yet recruiting
Est. primary completion 2027-12 · NCT07846358 · CT.gov ↗
What to watch
Phase 2Muscle Invasive Bladder Cancer (MIBC)Recruiting
Est. primary completion 2027-12 · NCT07296705 · CT.gov ↗
What to watch
Phase 2Extensive Stage Lung Small Cell CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07172412 · CT.gov ↗
What to watch
Phase 2ESCC, Total Neoadjuvant Treatment, Pathological Complete ResponseRecruiting
Est. primary completion 2027-12 · NCT06764355 · CT.gov ↗
What to watch
Phase 2Biliary Tract CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07099547 · CT.gov ↗
What to watch
Phase 2Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Tislelizumab, ctDNAActive not recruiting
Est. primary completion 2027-12-01 · NCT07136077 · CT.gov ↗
What to watch
Phase 2NSCLC, Tislelizumab, Chemotherapy, Hypofractionated RadiotherapyRecruiting
Est. primary completion 2027-12-10 · NCT07085182 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorRecruiting
Est. primary completion 2027-12-15 · NCT07669415 · CT.gov ↗
What to watch
Phase 1/2Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell LymphomaRecruiting
Est. primary completion 2027-12-30 · NCT07502768 · CT.gov ↗
What to watch
Phase 3Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck CarcinomaRecruiting
Est. primary completion 2027-12-30 · NCT06258811 · CT.gov ↗
What to watch
Early phase / not applicableInitially Unresectable Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07480382 · CT.gov ↗
What to watch
Phase 1Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07077369 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT06596473 · CT.gov ↗
What to watch
Phase 2NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)Recruiting
Est. primary completion 2027-12-31 · NCT07528274 · CT.gov ↗
What to watch
Phase 2Upper Tract Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07584733 · CT.gov ↗
What to watch
Phase 2TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical StudyNot yet recruiting
Est. primary completion 2027-12-31 · NCT06781112 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma, Local RecurrenceNot yet recruiting
Est. primary completion 2027-12-31 · NCT07331428 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06764251 · CT.gov ↗
What to watch
Phase 2Extensive Stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2027-12-31 · NCT07425795 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma, Pleomorphic Liposarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) …Recruiting
Est. primary completion 2027-12-31 · NCT06849986 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced TumorRecruiting
Est. primary completion 2027-12-31 · NCT07370337 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCCActive not recruiting
Est. primary completion 2027-12-31 · NCT06673693 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Follicular LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07418190 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07721103 · CT.gov ↗
What to watch
Early phase / not applicableAdvanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07068542 · CT.gov ↗
What to watch
2028 (57)
January 2028 (3)
Phase 1Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV …Recruiting
Est. primary completion 2028-01-01 · NCT05526924 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-01-31 · NCT07678580 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-01-31 · NCT07463248 · CT.gov ↗
What to watch
February 2028 (3)
Phase 2Nasopharyngeal Carcinoma (NPC)Not yet recruiting
Est. primary completion 2028-02 · NCT07388758 · CT.gov ↗
What to watch
Phase 2Stage III NSCLCRecruiting
Est. primary completion 2028-02-01 · NCT07264647 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-02-28 · NCT07733180 · CT.gov ↗
What to watch
March 2028 (7)
Phase 1Advanced or Recurrent Solid TumorsRecruiting
Est. primary completion 2028-03 · NCT06541639 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2028-03 · NCT05502250 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-03 · NCT06722183 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-03 · NCT07363512 · CT.gov ↗
What to watch
Phase 1/2Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor, Tislelizumab, GEJ AdenocarcinomaNot yet recruiting
Est. primary completion 2028-03-30 · NCT06871527 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2028-03-31 · NCT06349837 · CT.gov ↗
What to watch
Phase 2Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-31 · NCT07109401 · CT.gov ↗
What to watch
April 2028 (6)
Phase 1/2Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), ImmunotherapyRecruiting
Est. primary completion 2028-04 · NCT07244705 · CT.gov ↗
What to watch
Phase 2Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma RefractoryRecruiting
Est. primary completion 2028-04-01 · NCT07058103 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2028-04-01 · NCT06793917 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant TherapyRecruiting
Est. primary completion 2028-04-30 · NCT07601737 · CT.gov ↗
What to watch
Phase 2Gastric or Esophagogastric Junction AdenocarcinomaRecruiting
Est. primary completion 2028-04-30 · NCT07569068 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Cancinoma (NPC), Nasopharyngeal CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT07373990 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Gastric CarcinomaNot yet recruiting
Est. primary completion 2028-05-15 · NCT06944496 · CT.gov ↗
What to watch
June 2028 (6)
Phase 1Pancreatic CancerRecruiting
Est. primary completion 2028-06 · NCT07671339 · CT.gov ↗
What to watch
Phase 2Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07685704 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT07290985 · CT.gov ↗
What to watch
Phase 1Advanced Non-small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06868732 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-06-30 · NCT07609667 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-06-30 · NCT07047586 · CT.gov ↗
What to watch
July 2028 (6)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-07 · NCT06529523 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-07-01 · NCT07655661 · CT.gov ↗
What to watch
Phase 2Cholangiocarcinoma, Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2028-07-01 · NCT06903273 · CT.gov ↗
What to watch
Phase 2Esophageal Cancer Stage IIINot yet recruiting
Est. primary completion 2028-07-01 · NCT06965829 · CT.gov ↗
What to watch
Phase 4Advanced NSCLCNot yet recruiting
Est. primary completion 2028-07-01 · NCT06356675 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-07-31 · NCT07686926 · CT.gov ↗
What to watch
August 2028 (2)
Phase 1/2Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast CancerNot yet recruiting
Est. primary completion 2028-08 · NCT07681297 · CT.gov ↗
What to watch
Phase 2New Diagnosed Angioimmunoblastic T-Cell LymphomaRecruiting
Est. primary completion 2028-08-01 · NCT07168317 · CT.gov ↗
What to watch
September 2028 (3)
Phase 3NSCLC Stage IVRecruiting
Est. primary completion 2028-09 · NCT06745908 · CT.gov ↗
What to watch
Phase 2NSCLC, Stage IIIA, NSCLC (non-small Cell Lung Cancer)Not yet recruiting
Est. primary completion 2028-09-08 · NCT06614231 · CT.gov ↗
What to watch
Phase 1RAS Mutation, Advanced Solid Tumor, Metastatic Solid TumorRecruiting
Est. primary completion 2028-09-30 · NCT07746141 · CT.gov ↗
What to watch
October 2028 (9)
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2028-10 · NCT06093061 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomasRecruiting
Est. primary completion 2028-10 · NCT05582265 · CT.gov ↗
What to watch
Phase 3AdenocarcinomaRecruiting
Est. primary completion 2028-10 · NCT07385703 · CT.gov ↗
What to watch
Phase 1EGFR-TKI-resistant Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07842887 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT05627115 · CT.gov ↗
What to watch
Phase 2Non Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07432984 · CT.gov ↗
What to watch
Phase 2Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, Therapeutic, Conversion TherapyNot yet recruiting
Est. primary completion 2028-10-31 · NCT07561983 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)Not yet recruiting
Est. primary completion 2028-10-31 · NCT07812467 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-31 · NCT07131319 · CT.gov ↗
What to watch
November 2028 (2)
December 2028 (9)
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07128693 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07554456 · CT.gov ↗
What to watch
Phase 4Limited-stage Small Cell Lung Cancer (LS-SCLC)Not yet recruiting
Est. primary completion 2028-12-10 · NCT07485920 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12-30 · NCT07518706 · CT.gov ↗
What to watch
Phase 1Bladder Urothelial Carcinoma, Lymph Node MetastasisEnrolling by invitation
Est. primary completion 2028-12-31 · NCT07353294 · CT.gov ↗
What to watch
Phase 1/2Malignant TumorsNot yet recruiting
Est. primary completion 2028-12-31 · NCT07694765 · CT.gov ↗
What to watch
Phase 2Digestive System NeoplasmsNot yet recruiting
Est. primary completion 2028-12-31 · NCT07196540 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07039162 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07700667 · CT.gov ↗
What to watch
2029 (27)
January 2029 (1)
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2029-01-15 · NCT07328009 · CT.gov ↗
What to watch
February 2029 (3)
Phase 2HCC - Hepatocellular Carcinoma, DiabetesNot yet recruiting
Est. primary completion 2029-02 · NCT07557914 · CT.gov ↗
What to watch
Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-02-20 · NCT07408609 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, Solid TumorRecruiting
Est. primary completion 2029-02-28 · NCT05981703 · CT.gov ↗
What to watch
March 2029 (2)
April 2029 (3)
Phase 2Large B-cell LymphomaRecruiting
Est. primary completion 2029-04 · NCT06167785 · CT.gov ↗
What to watch
Phase 3Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer, Soft Tissue SarcomaRecruiting
Est. primary completion 2029-04 · NCT06332274 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2029-04-30 · NCT07414836 · CT.gov ↗
What to watch
May 2029 (2)
June 2029 (5)
Phase 4Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2029-06 · NCT07744698 · CT.gov ↗
What to watch
Phase 1/2Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C MutationRecruiting
Est. primary completion 2029-06-11 · NCT07468071 · CT.gov ↗
What to watch
Phase 3Gastric CarcinomaRecruiting
Est. primary completion 2029-06-30 · NCT07315750 · CT.gov ↗
What to watch
Early phase / not applicableNasopharyngeal Cancinoma (NPC)Active not recruiting
Est. primary completion 2029-06-30 · NCT07248696 · CT.gov ↗
What to watch
July 2029 (2)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-07 · NCT07729592 · CT.gov ↗
What to watch
Phase 2Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy, Consolidation Therapy, Non-small Cell Lung CancerRecruiting
Est. primary completion 2029-07-19 · NCT07086456 · CT.gov ↗
What to watch
August 2029 (2)
September 2029 (1)
Phase 3Gastroesophageal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07763171 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-10 · NCT07205731 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2/3Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET ScanRecruiting
Est. primary completion 2029-11-15 · NCT06563245 · CT.gov ↗
What to watch
December 2029 (4)
Phase 2HPV-unrelated Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12 · NCT07776340 · CT.gov ↗
What to watch
Phase 3Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2029-12 · NCT07502300 · CT.gov ↗
What to watch
Phase 1Pseudomyxoma PeritoneiRecruiting
Est. primary completion 2029-12-31 · NCT07341360 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2029-12-31 · NCT06856837 · CT.gov ↗
What to watch
2030 (4)
January 2030 (2)
June 2030 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-06-30 · NCT07775040 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2TNBC, Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2030-12-14 · NCT07271992 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 3Esophageal CancerNot yet recruiting
Est. primary completion 2031-06-28 · NCT06914011 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Non-small Cell Lung Cancer MetastaticNot yet recruiting
Est. primary completion 2031-10-30 · NCT07715396 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-12-31 · NCT07554521 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.